Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM5 | P08912 | 1/20 | 0.50 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.50 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 2/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.32 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21934661 | 0.98 | CHRM5 (0.48) | CHRM5ADRA2CACHEMAPTGAA | |
| SCHEMBL21934377 | 0.96 | CHRM5 (0.52) | CHRM5ADRA2CACHEMAPTGAA | |
| SCHEMBL2629515 | 0.96 | CHRM5 (0.56) | CHRM5ADRA2CACHEMAPTGAA | |
| SCHEMBL12563402 | 0.94 | CHRM5 (0.59) | CHRM5ADRA2CACHEMAPTGAA | |
| SCHEMBL118241 | 0.89 | CHRM5 (0.41) | CHRM5ADRA2CACHE | |
| SCHEMBL21341878 | 0.88 | CHRM5 (0.40) | CHRM5ADRA2CACHE | |
| SCHEMBL19959047 | 0.87 | CHRM5 (0.39) | CHRM5ADRA2CACHE | |
| SCHEMBL24927414 | 0.84 | ACHE (0.41) | CHRM5ADRA2CACHEOPRM1OPRL1 | |
| SCHEMBL17282109 | 0.84 | NCF1 (0.38) | CHRM5ADRA2CACHEMAPT | |
| SCHEMBL23277857 | 0.83 | CHRM5 (0.50) | CHRM5ADRA2CACHESMN1; SMN2OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200317705-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | ARIAD PHARMACEUTICALS, INC. | 2020-10-08 | — | — | US | disclosed |
| US-20170218000-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | ARIAD PHARMACEUTICALS, INC. | 2017-08-03 | — | — | US | disclosed |
| US-20170218000-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | ARIAD PHARMACEUTICALS, INC. | 2017-08-03 | — | — | US | disclosed |
| US-20160376297-A1 | Phosphorous Derivatives as Kinase Inhibitors | ARIAD PHARMA INC (US) | 2016-12-29 | — | — | US | disclosed |
| US-9273077-B2 | Phosphorus derivatives as kinase inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2016-03-01 | — | — | US | disclosed |
| US-20150225436-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | ARIAD PHARMACEUTICALS, INC. (US) | 2015-08-13 | — | — | US | disclosed |
| US-9012462-B2 | Phosphorous derivatives as kinase inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2015-04-21 | — | — | US | disclosed |
| US-20140066406-A1 | Phosphorus Derivatives as Kinase Inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2014-03-06 | — | — | US | disclosed |
| US-20130225527-A1 | Phosphorus Derivatives as Kinase Inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2013-08-29 | — | — | US | disclosed |
| US-20130225528-A1 | Phosphorus Derivatives as Kinase Inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2013-08-29 | — | — | US | disclosed |
| US-20120202776-A1 | PHOSPHORUS DERIVATIVES AS KINASE INHIBITORS | ARIAD PHARMACEUTICALS, INC. (US) | 2012-08-09 | — | — | US | disclosed |
| US-20120202776-A1 | PHOSPHORUS DERIVATIVES AS KINASE INHIBITORS | ARIAD PHARMACEUTICALS, INC. (US) | 2012-08-09 | — | — | US | disclosed |
| US-20110152243-A1 | NOVEL THIENOPYRROLE COMPOUNDS | ABBOTT LABORATORIES (US) | 2011-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140066406-A1 | Phosphorus Derivatives as Kinase Inhibitors | PHKA1, PIK3CA, PHKA2 | CHRM5 4777/4885ADRA2C 3727/4885ACHE 2990/4885 |
| US-20170218000-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | MAP3K6, PIK3CA, MAP3K20 | CHRM5 4874/4885ADRA2C 4471/4885ACHE 4457/4885 |
| US-20150225436-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | MAP3K6, PIK3CA, MAP3K20 | CHRM5 4874/4885ADRA2C 4451/4885ACHE 4520/4885 |
| US-20110152243-A1 | NOVEL THIENOPYRROLE COMPOUNDS | TPMT, TSLP, THPO | CHRM5 3455/4885ADRA2C 200/4885ACHE 4127/4885 |
| US-20120202776-A1 | PHOSPHORUS DERIVATIVES AS KINASE INHIBITORS | PHKA1, PIK3CA, PHKA2 | CHRM5 4722/4885ADRA2C 3481/4885ACHE 3010/4885 |
| US-20160376297-A1 | Phosphorous Derivatives as Kinase Inhibitors | MAP3K6, PIK3CA, MAP3K20 | CHRM5 4874/4885ADRA2C 4451/4885ACHE 4520/4885 |
| US-20200317705-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | MAP3K6, PIK3CA, MAP3K20 | CHRM5 4874/4885ADRA2C 4471/4885ACHE 4457/4885 |
| US-20130225527-A1 | Phosphorus Derivatives as Kinase Inhibitors | PHKA1, PIK3CA, PHKA2 | CHRM5 4777/4885ADRA2C 3727/4885ACHE 2990/4885 |
| US-20130225528-A1 | Phosphorus Derivatives as Kinase Inhibitors | PHKA1, PIK3CA, PHKA2 | CHRM5 4777/4885ADRA2C 3727/4885ACHE 2990/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.